Alemtuzumab for the treatment of multiple sclerosis.

MedStar author(s):
Citation: Expert Opinion on Biological Therapy. 18(3):323-334, 2018 03.PMID: 29309202Institution: MedStar Union Memorial HospitalForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Alemtuzumab/tu [Therapeutic Use] | *Multiple Sclerosis, Relapsing-Remitting/dt [Drug Therapy] | Alemtuzumab/ae [Adverse Effects] | Alemtuzumab/pk [Pharmacokinetics] | CD52 Antigen/im [Immunology] | Clinical Trials as Topic | Half-Life | Humans | Magnetic Resonance Imaging | Multiple Sclerosis, Relapsing-Remitting/dg [Diagnostic Imaging] | Multiple Sclerosis, Relapsing-Remitting/pa [Pathology] | Natalizumab/pk [Pharmacokinetics] | Natalizumab/tu [Therapeutic Use] | Product Surveillance, Postmarketing | Treatment OutcomeYear: 2018ISSN:
  • 1471-2598
Name of journal: Expert opinion on biological therapyAbstract: Introduction Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future. Expert opinion Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier.All authors: Bagnato F, Bozkurt S, Evan JR, Thomas NCFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-01-18
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29309202 Available 29309202

Introduction Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future. Expert opinion Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier.

English

Powered by Koha